South Africa’s Aspen Pharmacare could spend some $800 million on acquisitions, its deputy CEO said, as Africa’s biggest generic drugs maker looks for further targets, particularly in Latin America. Aspen, which paid about 6.5 billion rand ($879 million) for the generics business of Australia’s Sigma Pharmaceuticals this year, would be willing to do a similar deal to broaden its presence, Gus Attridge told Reuters. “We spent about 6 billion rand on the Sigma deal and that increased our debt, but we have already brought that down quite significantly,” he said.
